• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

作者信息

Papamichael Konstantinos, Cheifetz Adam S

机构信息

Center for Inflammatory Bowel Diseases, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Center for Inflammatory Bowel Diseases, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

出版信息

J Crohns Colitis. 2016 May;10(5):507-9. doi: 10.1093/ecco-jcc/jjw041. Epub 2016 Feb 13.

DOI:10.1093/ecco-jcc/jjw041
PMID:26874348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4957461/
Abstract
摘要

相似文献

1
Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.阿达木单抗药物水平升高与克罗恩病患者的黏膜愈合相关。
J Crohns Colitis. 2016 May;10(5):507-9. doi: 10.1093/ecco-jcc/jjw041. Epub 2016 Feb 13.
2
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].[阿达木单抗治疗腔外型和瘘管型克罗恩病患者第一年疗效、黏膜愈合及剂量强化的预测因素。来自匈牙利的全国性数据]
Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200.
3
The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease.阿达木单抗对克罗恩病内镜愈合及黏膜细胞因子基因表达正常化的诱导作用。
Scand J Gastroenterol. 2012 Oct;47(10):1200-10. doi: 10.3109/00365521.2012.711853. Epub 2012 Aug 6.
4
IBD: Mucosal healing--EXTENDing our knowledge in Crohn's disease.炎症性肠病：黏膜愈合——扩展我们对克罗恩病的认识
Nat Rev Gastroenterol Hepatol. 2012 Apr 24;9(6):309-11. doi: 10.1038/nrgastro.2012.77.
5
Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.阿达木单抗药代动力学与炎症性肠病患者黏膜愈合的关系。
Clin Gastroenterol Hepatol. 2014 Jan;12(1):80-84.e2. doi: 10.1016/j.cgh.2013.07.010. Epub 2013 Jul 23.
6
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.早期临床缓解和 CRP 正常化是预测阿达木单抗治疗克罗恩病第一年疗效、黏膜愈合和剂量升级的最强指标。
Aliment Pharmacol Ther. 2011 Oct;34(8):911-22. doi: 10.1111/j.1365-2036.2011.04827.x. Epub 2011 Aug 24.
7
[Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].[阿达木单抗治疗成人克罗恩病——奥地利胃肠病学和肝病学会炎症性肠病工作组共识报告更新]
Z Gastroenterol. 2013 Sep;51(9):1101-9. doi: 10.1055/s-0033-1350165. Epub 2013 Aug 30.
8
A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.通过胶囊内镜检测对小肠克罗恩病进行为期52周的前瞻性黏膜愈合评估。
J Crohns Colitis. 2014 Dec;8(12):1601-9. doi: 10.1016/j.crohns.2014.09.005. Epub 2014 Sep 23.
9
Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.局部阿达木单抗注射治疗肛瘘型肛周克罗恩病的有效性和安全性：一项初步研究。
Dis Colon Rectum. 2012 Aug;55(8):870-5. doi: 10.1097/DCR.0b013e31825af532.
10
Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice.抗肿瘤坏死因子初治的克罗恩病患者对阿达木单抗的临床、生物学及内镜反应：临床实践中疗效的预测因素
Eur J Gastroenterol Hepatol. 2015 Apr;27(4):430-5. doi: 10.1097/MEG.0000000000000296.

引用本文的文献

1
Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets.溃疡性结肠炎患者接受阿达木单抗治疗期间肠道微生物群组成的动态变化：对治疗反应预测和治疗靶点的意义
Gut Pathog. 2024 Aug 26;16(1):44. doi: 10.1186/s13099-024-00637-5.
2
Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab.即时检验可能有助于在使用阿达木单抗的积极策略中对炎症性肠病患者进行治疗药物监测。
J Clin Med. 2020 Aug 25;9(9):2739. doi: 10.3390/jcm9092739.
3
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.抗 TNF 在儿童和青少年炎症性肠病中的应用综述
Int J Mol Sci. 2019 May 23;20(10):2529. doi: 10.3390/ijms20102529.
4
Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.维持阿达木单抗浓度与炎症性肠病的生化、内镜和组织学缓解相关。
Dig Dis Sci. 2018 Nov;63(11):3067-3073. doi: 10.1007/s10620-018-5202-5. Epub 2018 Jul 13.
5
Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.维持治疗期间血清英夫利昔单抗谷浓度与克罗恩病的生化、内镜和组织学缓解的关系。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2266-2271. doi: 10.1093/ibd/izy132.
6
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.儿童炎症性肠病的治疗药物监测
Curr Gastroenterol Rep. 2018 Apr 5;20(5):18. doi: 10.1007/s11894-018-0623-z.

本文引用的文献

1
Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.阿达木单抗药物水平升高与克罗恩病患者的黏膜愈合相关。
J Crohns Colitis. 2016 May;10(5):510-5. doi: 10.1093/ecco-jcc/jjw014. Epub 2016 Jan 18.
2
Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease.系统评价与荟萃分析：炎症性肠病维持治疗期间血清英夫利昔单抗水平与治疗结果
J Crohns Colitis. 2016 May;10(5):619-25. doi: 10.1093/ecco-jcc/jjw007. Epub 2016 Jan 13.
3
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.较高的阿达木单抗水平与克罗恩病和溃疡性结肠炎患者的组织学及内镜缓解相关。
Inflamm Bowel Dis. 2016 Feb;22(2):409-15. doi: 10.1097/MIB.0000000000000689.
4
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.英夫利昔单抗诱导治疗期间的浓度阈值与溃疡性结肠炎患者的短期黏膜愈合相关。
Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9. doi: 10.1016/j.cgh.2015.11.014. Epub 2015 Dec 8.
5
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.优化抗TNF-α治疗：英夫利昔单抗和阿达木单抗的血清水平与炎症性肠病患者的黏膜愈合相关。
Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2. doi: 10.1016/j.cgh.2015.10.025. Epub 2015 Oct 29.
6
Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis.抗肿瘤坏死因子谷浓度能否预测炎症性肠病患者的黏膜愈合？一项系统评价和Meta分析
J Clin Gastroenterol. 2016 Oct;50(9):733-41. doi: 10.1097/MCG.0000000000000441.
7
Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.在维持治疗下缓解期炎症性肠病患者的血清抗 TNF 抗体浓度、不良反应和生活质量。
J Crohns Colitis. 2015 Nov;9(11):973-81. doi: 10.1093/ecco-jcc/jjv116. Epub 2015 Jun 26.
8
Pharmacokinetics of adalimumab in Crohn's disease.阿达木单抗在克罗恩病中的药代动力学
Eur J Clin Pharmacol. 2015 Sep;71(9):1155-7. doi: 10.1007/s00228-015-1892-1. Epub 2015 Jun 27.
9
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.英夫利昔单抗经粪便流失与重度溃疡性结肠炎患者治疗应答不足相关。
Gastroenterology. 2015 Aug;149(2):350-5.e2. doi: 10.1053/j.gastro.2015.04.016. Epub 2015 Apr 25.
10
It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing.
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2384. doi: 10.1016/j.cgh.2015.03.031. Epub 2015 Apr 8.